Trial Profile

A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed and Cisplatin in Patients With Stage IV Non-small Cell Lung Cancer.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 14 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rabusertib (Primary) ; Cisplatin; Pemetrexed
Indications Malignant-mesothelioma; Non-small cell lung cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors Eli Lilly and Company

Most Recent Events

14 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
21 Apr 2014 Planned End Date changed from 1 Mar 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov.
30 Oct 2013 Planned end date changed from 1 Nov 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com